NCT00086255

Tiagabine for the Treatment of Cocaine Dependence - 1

Tiagabine for the Treatment of Cocaine Dependence

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 140 (planned)
• Sponsor: National Institute on Drug Abuse (NIDA) · NIH
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess tiagabine for the treatment of cocaine dependence.

Detailed description

To assess the efficacy and safety of tiagabine in reducing cocaine use in subjects with cocaine dependence. It is hypothesized that tiagabine treatment, compared to placebo, will be associated with fewer days of cocaine use as assessed by self-report confirmed with urine assays for benzoylecgonine (BE). This is a double-blind, placebo-controlled, parallel-group design study, in which, after screening and a 2-week baseline assessment period, subjects will be equally randomly assigned to 1 of 2 treatment groups, tiagabine or matched placebo.

Conditions

• Cocaine-Related Disorders

Interventions

Type	Name	Description
DRUG	Tiagabine

Timeline

• Start date: 2002-10-01
• Completion: 2004-06-01
• First posted: 2004-06-30
• Last updated: 2017-01-12

Locations

4 sites across 1 country: United States